China FDA Approves New Traditional Chinese Medicine Drug for Clinical Trials
Yicai Global
/SOURCE : Yicai
China FDA Approves New Traditional Chinese Medicine Drug for Clinical Trials

(Yicai Global) June 23 -- The China Food and Drug Administration has approved Jitongning, a new pain relief drug developed using traditional Chinese medicine, to begin clinical trials, the drug's creator said recently.

Tianjin-based Tasly Pharmaceutical Co. [SHA:600535], the firm behind Jitongning, said this is the first drug they've developed using only traditional Chinese medicine.

Its main purposes are to treat inflamed spines, general pain, restricted movement and other symptoms for patients with spinal arthritis, the company added.

There are currently no traditional Chinese medicine products on the market that compete with Jitongning.

Follow Yicai Global on
Keywords: MSCI , REGULATION , Chinese Medicine , Medicine